Eolas Therapeutics Secures Full Development Rights to AZD4041
10 Jul 2025 //
BUSINESSWIRE
Eolas Therapeutics and AstraZeneca Partner to Develop Orexin-1 Receptor Antagonist for Multiple Indications
01 Jul 2015 //
FIRST WORD PHARMA
10 Jul 2025 //
BUSINESSWIRE
01 Jul 2015 //
FIRST WORD PHARMA